CLS-014 first-in-class disease-modifying gene therapy for cancer
CLS-014 affects a new therapeutic target - cleaning deadly circulating extracellular DNA from the patient’s blood
CLS-014 breakthrough science to revolutionize cancer therapy
CLS Therapeutics is a biopharmaceutical company translating the new biology of cell-free DNA into novel therapeutic approaches for multiple cancers with unmet medical needs, beginning with our first program for pancreatic cancer.
The company’s first-in-class lead candidate CLS-014 is a novel adeno-associated vector Anc80 encoding hyperactive variant of human DNase I enzyme designed to clean deadly circulating extracellular DNA from patients’ blood.
CLS Therapeutics, founded by scientists and biotech entrepreneurs and guided by a team comprised of the brightest minds in the field of oncology and gene therapy, committed to advancing cutting-edge research to help cancer patients.
CLS Therapeutics works to deliver on the promise of circulating nucleic acid science to advance a new generation of transformative gene therapies for cancer patients.
We have built a team of internationally recognized experts in circulating nucleic acid research, gene therapy and oncology, transforming treatment of the worst curable gastrointestinal cancers that are of an unmet medical need by the discovery of a novel breakthrough therapeutic target.